PubMed چکیده/رکورد

Analysis of SOX2 and SOX17 expression in cervical HPV-associated adenocarcinoma in situ: Correlation with histologic variants.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

HPV-associated adenocarcinoma in situ (AIS) is the main precursor to endocervical adenocarcinoma. The differential immunoprofiles remain poorly characterized among HPV-associated AIS variants (such as usual-type and stratified mucin-producing intraepithelial lesion [SMILE]). This study aimed to investigate the expression of stem cell markers (SOX2 and SOX17) in 159 HPV-associated AIS (124 usual-type, 11 with intestinal differentiation, 24 SMILE) by immunohistochemistry. Compared to normal endocervical glands, AIS exhibited significantly increased expression of SOX2 (69.2% vs. 0, p < 0.001), but decreased SOX17 (40.9% vs. 98.1%, p < 0.001). Positive SOX2 and negative SOX17 had a specificity of 100% and 98.1% in the differential diagnosis of AIS from normal glands, respectively. SOX2 expression was significantly higher in SMILE (22/24, 91.7%) than in usual-type AIS (80/124, 64.5%, p = 0.030). In contrast, SOX17 expression was absent in all SMILE (0/24) and most AIS with intestinal differentiation (1/11, 9.1%), but was significantly higher in usual-type AIS (64/124, 51.6%, p < 0.001). The SOX2/SOX17 composite profile may aid in the diagnosis of AIS and its variants. The SOX2-positive (overexpression) /SOX17-negative profile suggest a divergent pathway with squamous differentiation potential in SMILE. These findings provide novel insights into the cellular histogenesis of AIS variants.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی

کلیدواژه‌ها

Adenocarcinoma in situCervixImmunohistochemistrySOX17SOX2
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real-world cohort.

BACKGROUND: Urine cytology is recommended for noninvasive detection of urothelial carcinoma (UC) but shows limited sensitivity, particularly in low-grade disease. Keratin 17 (K17) has emerged as a promising immunocytochemical marker. This study evaluated the diagnostic performance and interobserver agreement of K17 in a routine setting. METHODS: This prospective cross-sectional study included 184 urine samples from patients undergoing …

PubMed2026

A case report of primary prostate intravascular large B-cell lymphoma.

RATIONALE: Primary intravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive extranodal lymphoma that rarely affects the prostate. Its nonspecific clinical and laboratory features often lead to misdiagnosis as benign prostatic hyperplasia (BPH) or prostatitis, delaying appropriate treatment. We report a case of primary prostatic IVLBCL initially misdiagnosed as BPH, highlighting the diagnostic challenges and the importance …

PubMed2026

An immunohistochemical based assessment of murine double minute 2 (MDM2) and cyclin-dependent kinase 4 (CDK4) in jaw osteosarcoma and benign osseous lesions.

UNLABELLED: The diagnosis of primary bone tumours of the jaw often presents as a diagnostic dilemma. Overlap in clinical, radiological, and histological features between benign lesions like juvenile trabecular ossifying fibroma (JTOF); osteoblastoma (OB) and malignant tumours like low-grade osteosarcoma (LGOS) makes the diagnosis challenging. While osteosarcoma is a malignant tumour with poor prognosis requiring aggressive treatment, b…

PubMed2026

The human trophoblast cell-surface antigen 2 (TROP-2) expression on metastasized breast cancer.

PURPOSE: The antibody-drug conjugates (ADCs) sacituzumab govitecan (SG) and datopotamab deruxtecan target trophoblast cell surface antigen 2 (TROP-2) and have shown significant efficacy in HER2-negative metastatic breast cancer (mBC). As TROP-2 may serve as a target across multiple treatment lines, detailed information on TROP-2 expression over time is of great interest. METHODS: TROP-2 expression was analyzed in breast cancer (BC) sam…